Prognostic utility of pre-transplantation [18 F] fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma who underwent rituximab, dexamethasone, high-dose cytarabine, carboplatin salvage chemotherapy

British Journal of Haematology
Charles MesguichKrimo Bouabdallah

Abstract

We analysed the outcomes of 62 patients with refractory/relapsed diffuse large B-cell lymphoma (rrDLBCL) who had pre-transplantation fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) after R-DHAC (rituximab, dexamethasone, high-dose cytarabine, carboplatin) salvage chemotherapy, and were evaluated using Deauville criteria and total lesion glycolysis (TLG). A positive pre-transplantation PET/CT with Deauville score of 5 was associated with shorter progression-free survival (PFS) (P = 0·01), while a Deauville score of 4 was not predictive of outcome. Only pre-transplant TLG was significantly associated with both PFS (P = 0·005) and overall survival (P = 0·03). TLG deserves to be further investigated in prospective studies.

References

Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtNorbert Schmitz
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sally F BarringtonBruce D Cheson
Mar 5, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anne-Ségolène CottereauStéphanie Becker
Mar 11, 2016·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Pouya ZiaiOleg M Teytelboym

❮ Previous
Next ❯

Citations

Feb 4, 2021·Seminars in Nuclear Medicine·Heather A Jacene

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.